Mineralys Therapeutics, Inc. Insider Trading
MLYS
Insiders bought $8.76M and sold $27.9M on the open market.
89% of the selling was scheduled in advance under 10b5-1 plans. Director Brian Taylor Slingsby sold $3.01M on Sep 22 outside a plan.
Get an email when MLYS's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30 | Jon Congleton Chief Executive Officer | Sold10b5-1 plan | 75,000 | $25.46 | $1.91M | 12% | Form 4 |
| Sep 22 | Brian Taylor Slingsby Director | SoldNo plan | 104,320 | $28.81 | $3.01M | 1.3% | Form 4 |
| Sep 21 | Eric Warren Chief Commercial Officer | Sold10b5-1 plan | 7,438 | $28.12 | 209K | 16% | Form 4 |
| Sep 15 | Daphne Karydas Director | Sold10b5-1 plan | 3,000 | $28.58 | 86K | 33% | Form 4 |
| Aug 21 | Eric Warren Chief Commercial Officer | Sold10b5-1 plan | 7,437 | $25.98 | 193K | 16% | Form 4 |
| Aug 10 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 2,170 | $27.09 | 59K | 4.1% | Form 4 |
| Jul 21 | Eric Warren Chief Commercial Officer | Sold10b5-1 plan | 7,438 | $26.87 | 200K | 16% | Form 4 |
| Jul 17 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 416 | $26.53 | 11K | 0.8% | Form 4 |
| Jul 13 – 15 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 2 parts | 20,407 | $27.28 average | 557K | 28% | Form 4 |
| Jul 13 | Jon Congleton Chief Executive Officer | Sold10b5-1 plan | 10,700 | $27.24 | 291K | 1.7% | Form 4 |
| Jul 9 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 2,171 | $30.30 | 66K | 3.6% | Form 4 |
| Jun 30 | Jon Congleton Chief Executive Officer | Sold10b5-1 plan 2 parts | 75,000 | $26.14 average | $1.96M | 11% | Form 4 |
| Jun 26 | Eric Warren Chief Commercial Officer | Sold10b5-1 plan | 104,124 | $25.90 | $2.7M | 73% | Form 4 |
| Jun 15 – 17 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 2 parts | 14,474 | $24.19 average | 350K | 20% | Form 4 |
| Jun 17 | Daphne Karydas Director | Sold10b5-1 plan | 3,000 | $25.00 | 75K | 33% | Form 4 |
| Jun 10 – 12 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 2 parts | 8,519 | $24.20 average | 206K | 12% | Form 4 |
| May 18 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 417 | $27.55 | 11K | 0.7% | Form 4 |
| May 11 – 13 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 3 parts | 22,575 | $28.91 average | 653K | 26% | Form 4 |
| Apr 17 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 416 | $31.33 | 13K | 0.6% | Form 4 |
| Apr 13 – 15 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 2 parts | 20,406 | $26.89 average | 549K | 23% | Form 4 |
| Apr 13 | Jon Congleton Chief Executive Officer | Sold10b5-1 plan | 15,730 | $26.83 | 422K | 2.2% | Form 4 |
| Apr 9 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 2,170 | $27.38 | 59K | 2.8% | Form 4 |
| Mar 31 | Daphne Karydas Director | Sold10b5-1 plan | 3,000 | $25.00 | 75K | 33% | Form 4 |
| Mar 31 | Jon Congleton Chief Executive Officer | Sold10b5-1 plan 3 parts | 75,000 | $26.27 average | $1.97M | 9.6% | Form 4 |
| Mar 27 – 30 | Rajeev M. Shah Director | Bought 2 parts | 369,000 | $23.75 average | $8.76M | 6.8% | Form 4 |
| Mar 17 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 417 | $25.65 | 11K | 0.5% | Form 4 |
| Mar 12 – 13 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 4 parts | 20,406 | $26.61 average | 543K | 21% | Form 4 |
| Mar 9 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 2,171 | $26.84 | 58K | 2.6% | Form 4 |
| Feb 17 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 417 | $27.59 | 12K | 0.9% | Form 4 |
| Feb 12 – 13 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 5 parts | 20,404 | $27.93 average | 570K | 32% | Form 4 |
| Feb 9 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 2,171 | $30.21 | 66K | 4.1% | Form 4 |
| Jan 20 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan | 416 | $32.10 | 13K | 0.8% | Form 4 |
| Jan 13 – 14 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 2 parts | 19,076 | $32.67 average | 623K | 27% | Form 4 |
| Jan 12 | Adam Scott Levy CFO and Secretary | Sold10b5-1 plan | 10,758 | $32.14 | 346K | 55% | Form 4 |
| Jan 9 – 12 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 2 parts | 8,518 | $32.56 average | 277K | 12% | Form 4 |
| Jan 12 | Jon Congleton Chief Executive Officer | Sold10b5-1 plan 2 parts | 16,236 | $32.62 average | 530K | 2.5% | Form 4 |
| Jan 2 – 5 | David Malcom Rodman Chief Medical Officer | Sold10b5-1 plan 3 parts | 262,752 | $35.25 average | $9.26M | 81% | Form 4 |
| Nov 20, 2025 | Catalys Pacific Fund, LP Large holder | SoldNo plan | 1,000,000 | $43.35 | $43.4M | 11% | Form 4 |
| Nov 13, 2025 | Daphne Karydas Director | SoldNo plan 2 parts | 15,000 | $45.99 average | 690K | 100% | Form 4 |
| Nov 11, 2025 – Nov 13, 2025 | Alexander M Gold Director | SoldNo plan 5 parts | 34,675 | $45.45 average | $1.58M | 100% | Form 4 |
- Sep 3010b5-1 planJon CongletonChief Executive Officer · sold 75,000 at $25.46$1.91M12% of stake
- Sep 22No planBrian Taylor SlingsbyDirector · sold 104,320 at $28.81$3.01M1.3% of stake
- Sep 2110b5-1 planEric WarrenChief Commercial Officer · sold 7,438 at $28.12209K16% of stake
- Sep 1510b5-1 planDaphne KarydasDirector · sold 3,000 at $28.5886K33% of stake
- Aug 2110b5-1 planEric WarrenChief Commercial Officer · sold 7,437 at $25.98193K16% of stake
- Aug 1010b5-1 planDavid Malcom RodmanChief Medical Officer · sold 2,170 at $27.0959K4.1% of stake
- Jul 2110b5-1 planEric WarrenChief Commercial Officer · sold 7,438 at $26.87200K16% of stake
- Jul 1710b5-1 planDavid Malcom RodmanChief Medical Officer · sold 416 at $26.5311K0.8% of stake
- Jul 13 – 1510b5-1 planDavid Malcom RodmanChief Medical Officer · sold 20,407 at avg $27.28557K28% of stake
- Jul 1310b5-1 planJon CongletonChief Executive Officer · sold 10,700 at $27.24291K1.7% of stake
- Jul 910b5-1 planDavid Malcom RodmanChief Medical Officer · sold 2,171 at $30.3066K3.6% of stake
- Jun 3010b5-1 planJon CongletonChief Executive Officer · sold 75,000 at avg $26.14$1.96M11% of stake
- Jun 2610b5-1 planEric WarrenChief Commercial Officer · sold 104,124 at $25.90$2.7M73% of stake
- Jun 15 – 1710b5-1 planDavid Malcom RodmanChief Medical Officer · sold 14,474 at avg $24.19350K20% of stake
- Jun 1710b5-1 planDaphne KarydasDirector · sold 3,000 at $25.0075K33% of stake
- Jun 10 – 1210b5-1 planDavid Malcom RodmanChief Medical Officer · sold 8,519 at avg $24.20206K12% of stake
- May 1810b5-1 planDavid Malcom RodmanChief Medical Officer · sold 417 at $27.5511K0.7% of stake
- May 11 – 1310b5-1 planDavid Malcom RodmanChief Medical Officer · sold 22,575 at avg $28.91653K26% of stake
- Apr 1710b5-1 planDavid Malcom RodmanChief Medical Officer · sold 416 at $31.3313K0.6% of stake
- Apr 13 – 1510b5-1 planDavid Malcom RodmanChief Medical Officer · sold 20,406 at avg $26.89549K23% of stake
- Apr 1310b5-1 planJon CongletonChief Executive Officer · sold 15,730 at $26.83422K2.2% of stake
- Apr 910b5-1 planDavid Malcom RodmanChief Medical Officer · sold 2,170 at $27.3859K2.8% of stake
- Mar 3110b5-1 planDaphne KarydasDirector · sold 3,000 at $25.0075K33% of stake
- Mar 3110b5-1 planJon CongletonChief Executive Officer · sold 75,000 at avg $26.27$1.97M9.6% of stake
- Mar 27 – 30Rajeev M. ShahDirector · bought 369,000 at avg $23.75$8.76M6.8% of stake
- Mar 1710b5-1 planDavid Malcom RodmanChief Medical Officer · sold 417 at $25.6511K0.5% of stake
- Mar 12 – 1310b5-1 planDavid Malcom RodmanChief Medical Officer · sold 20,406 at avg $26.61543K21% of stake
- Mar 910b5-1 planDavid Malcom RodmanChief Medical Officer · sold 2,171 at $26.8458K2.6% of stake
- Feb 1710b5-1 planDavid Malcom RodmanChief Medical Officer · sold 417 at $27.5912K0.9% of stake
- Feb 12 – 1310b5-1 planDavid Malcom RodmanChief Medical Officer · sold 20,404 at avg $27.93570K32% of stake
- Feb 910b5-1 planDavid Malcom RodmanChief Medical Officer · sold 2,171 at $30.2166K4.1% of stake
- Jan 2010b5-1 planDavid Malcom RodmanChief Medical Officer · sold 416 at $32.1013K0.8% of stake
- Jan 13 – 1410b5-1 planDavid Malcom RodmanChief Medical Officer · sold 19,076 at avg $32.67623K27% of stake
- Jan 1210b5-1 planAdam Scott LevyCFO and Secretary · sold 10,758 at $32.14346K55% of stake
- Jan 9 – 1210b5-1 planDavid Malcom RodmanChief Medical Officer · sold 8,518 at avg $32.56277K12% of stake
- Jan 1210b5-1 planJon CongletonChief Executive Officer · sold 16,236 at avg $32.62530K2.5% of stake
- Jan 2 – 510b5-1 planDavid Malcom RodmanChief Medical Officer · sold 262,752 at avg $35.25$9.26M81% of stake
- Nov 20, 2025No planCatalys Pacific Fund, LPLarge holder · sold 1,000,000 at $43.35$43.4M11% of stake
- Nov 13, 2025No planDaphne KarydasDirector · sold 15,000 at avg $45.99690K100% of stake
- Nov 11, 2025 – Nov 13, 2025No planAlexander M GoldDirector · sold 34,675 at avg $45.45$1.58M100% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with MLYS
Held by ETFs
MLYS is in 37 US ETFs. The largest of them, with MLYS's weight in each:
Spot a number that looks wrong? Check it in MLYS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MLYS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.